ERBB2 and breast carcinoma: The study has reported that α‐mangostin exerts anti‐cancer activity in human breast cancer T47D cells by inhibiting HER2 activation and the downstream PI3K/Akt and ERK signaling pathways (Kritsanawong et al. 2016).